A new National Patient Safety Alert has been issued relating to the supply issues being experienced within GLP-1 RA treatments. This supersedes the previous patient safety alert.
The new alert reflects an increase in supply of Rybelsus® tablets (oral semaglutide), which is now sufficient to allow for new initiations of this medicine for people with type 2 diabetes in whom a GLP-1 RA is clinically appropriate. Please note there are new actions to be completed, including the review of people currently prescribed Byetta® and Victoza® who, due to product discontinuation and stock issues respectively, should be switched to Rybelsus®.